Foerster J, et al. - In the present study, the researchers sought to measure the cost savings achieved by phototherapy by delaying alternative treatments. Costs accruing through the UK-wide established treatment pathway with and without phototherapy have been examined in this analysis. Using drug tariff, laboratory costs, estate rates, and clinic review costs, direct and indirectly incurred drug treatment costs were calculated. Data reported that medium annual cost savings per patient, respectively, were £2200 for NB-UVB and £3700 if both NB-UVB and PUVA courses were administered. Through implementing and/or widening access to phototherapy, healthcare providers may achieve significant cost savings.